Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

NCT01849874 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01849874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01849874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 27, 2013
Completion date
August 23, 2022
Enrollment
341 (actual)
Sites
226

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade serous fallopian tube cancer, low-grade serous ovarian cancer, low-grade serous peritoneal cancer